• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus.

作者信息

Chiricozzi Andrea, Garcovich Simone, Malvaso Dalma, Giovanardi Giulia, Peris Ketty

机构信息

Dermatologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy.

出版信息

Int J Dermatol. 2020 Nov;59(11):1423-1424. doi: 10.1111/ijd.15209. Epub 2020 Sep 23.

DOI:10.1111/ijd.15209
PMID:32966593
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7536954/
Abstract
摘要

相似文献

1
COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus.一名接受司库奇尤单抗治疗、患有化脓性汗腺炎和系统性红斑狼疮的患者感染了新冠病毒。
Int J Dermatol. 2020 Nov;59(11):1423-1424. doi: 10.1111/ijd.15209. Epub 2020 Sep 23.
2
Tildrakizumab in the treatment of moderate-to-severe hidradenitis suppurativa.替拉珠单抗治疗中度至重度化脓性汗腺炎
Australas J Dermatol. 2020 Nov;61(4):e488-e490. doi: 10.1111/ajd.13377. Epub 2020 Jul 6.
3
Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.2019 年冠状病毒病（COVID-19）在自身免疫和炎症性疾病中的表现：不良结局的临床特征。
Rheumatol Int. 2020 Oct;40(10):1593-1598. doi: 10.1007/s00296-020-04676-4. Epub 2020 Aug 13.
4
Improvement of Libman-Sacks Endocarditis With Combined Hydroxychloroquine-Vitamin K Antagonist Therapy in a Primary Antiphospholipid Syndrome Patient.原发性抗磷脂综合征患者联合羟氯喹-维生素K拮抗剂治疗改善Libman-Sacks心内膜炎
Circ J. 2018 Aug 24;82(9):2380-2382. doi: 10.1253/circj.CJ-17-1131. Epub 2018 Feb 22.
5
Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics.2019年冠状病毒病大流行期间系统性红斑狼疮患者的羟氯喹短缺情况：系统性红斑狼疮国际协作诊所的经验
Ann Rheum Dis. 2021 Feb;80(2):1-2. doi: 10.1136/annrheumdis-2020-218164. Epub 2020 Jun 25.
6
Ixekizumab in hidradenitis suppurativa in a psoriatic patient.司库奇尤单抗治疗一名银屑病患者的化脓性汗腺炎
G Ital Dermatol Venereol. 2020 Dec;155(6):788-789. doi: 10.23736/S0392-0488.18.06135-7. Epub 2019 Jan 9.
7
Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.COVID-19 患者伴系统性红斑狼疮，SARS-CoV-2 RNA 阳性复发后成功康复：病例报告及文献复习。
Clin Rheumatol. 2020 Sep;39(9):2803-2810. doi: 10.1007/s10067-020-05230-0. Epub 2020 Jul 28.
8
SARS CoV-2 infection among patients using immunomodulatory therapies.使用免疫调节疗法的患者中的新型冠状病毒2型感染
Ann Rheum Dis. 2021 Feb;80(2):269-271. doi: 10.1136/annrheumdis-2020-218580. Epub 2020 Aug 5.
9
Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients.羟氯喹在系统性红斑狼疮及抗磷脂抗体阳性患者中预防血栓形成的应用。
Curr Rheumatol Rep. 2011 Feb;13(1):77-80. doi: 10.1007/s11926-010-0141-y.
10
Systemic lupus erythematosus, celiac disease and antiphospholipid antibody syndrome: a rare association.
Rheumatol Int. 2008 Sep;28(11):1179-80. doi: 10.1007/s00296-008-0603-y. Epub 2008 May 17.

引用本文的文献

1
Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa.白细胞介素-17抑制剂在化脓性汗腺炎治疗中的应用
BioDrugs. 2025 Jan;39(1):53-74. doi: 10.1007/s40259-024-00687-w. Epub 2024 Nov 28.
2
Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies.化脓性汗腺炎的新兴治疗方法及临床试验概况 第一部分：局部和全身药物治疗
Dermatol Ther (Heidelb). 2023 Aug;13(8):1661-1697. doi: 10.1007/s13555-023-00956-6. Epub 2023 Jul 4.
3
New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa.深入了解化脓性汗腺炎的分子发病机制和免疫调节治疗。
Int J Mol Sci. 2023 May 8;24(9):8428. doi: 10.3390/ijms24098428.

本文引用的文献

1
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study.羟氯喹和阿奇霉素联合治疗至少随访 6 天的 80 例 COVID-19 患者的临床和微生物学效果：一项前瞻性观察研究。
Travel Med Infect Dis. 2020 Mar-Apr;34:101663. doi: 10.1016/j.tmaid.2020.101663. Epub 2020 Apr 11.
2
Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial.司库奇尤单抗治疗中度至重度化脓性汗腺炎：一项开放标签试验的结果
J Am Acad Dermatol. 2020 Jun;82(6):1524-1526. doi: 10.1016/j.jaad.2020.02.005. Epub 2020 Feb 7.
3
Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa.一项开放标签、研究者发起的单中心探索性试验，评估抗白细胞介素-17A单克隆抗体司库奇尤单抗用于中度至重度化脓性汗腺炎患者的疗效。
Br J Dermatol. 2019 Sep;181(3):609-611. doi: 10.1111/bjd.17822. Epub 2019 May 12.
4
A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab.一例难治性狼疮性肾炎合并寻常型银屑病患者经司库奇尤单抗治疗后病情得到控制。
Lupus. 2018 Jun;27(7):1202-1206. doi: 10.1177/0961203318762598. Epub 2018 Mar 9.
5
Anti-Tumor Necrosis Factor-α Induced Systemic Lupus Erythematosus().抗肿瘤坏死因子-α诱导的系统性红斑狼疮（）
Open Rheumatol J. 2012;6:315-9. doi: 10.2174/1874312901206010315. Epub 2012 Nov 16.